Vinva Investment Management Ltd Sells 10,085 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Vinva Investment Management Ltd cut its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 34.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,524 shares of the biotechnology company’s stock after selling 10,085 shares during the period. Vinva Investment Management Ltd’s holdings in United Therapeutics were worth $6,983,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of UTHR. Thrivent Financial for Lutherans grew its position in United Therapeutics by 33.7% in the third quarter. Thrivent Financial for Lutherans now owns 14,332 shares of the biotechnology company’s stock valued at $5,136,000 after acquiring an additional 3,615 shares during the period. Quest Partners LLC grew its position in United Therapeutics by 347.7% in the third quarter. Quest Partners LLC now owns 1,249 shares of the biotechnology company’s stock valued at $448,000 after acquiring an additional 970 shares during the period. Pathstone Holdings LLC grew its position in United Therapeutics by 4.1% in the third quarter. Pathstone Holdings LLC now owns 4,118 shares of the biotechnology company’s stock valued at $1,476,000 after acquiring an additional 163 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in United Therapeutics in the third quarter valued at $344,000. Finally, PNC Financial Services Group Inc. grew its position in United Therapeutics by 14.9% in the third quarter. PNC Financial Services Group Inc. now owns 3,179 shares of the biotechnology company’s stock valued at $1,139,000 after acquiring an additional 412 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,255 shares of company stock worth $32,614,521. Insiders own 11.90% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group boosted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Trading Down 2.7 %

Shares of UTHR opened at $314.12 on Wednesday. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The stock has a market cap of $14.11 billion, a P/E ratio of 13.80, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The stock’s 50-day moving average price is $348.15 and its two-hundred day moving average price is $357.92.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same quarter last year, the business earned $4.36 earnings per share. As a group, equities analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.